New KRAS-Targeting Drug for Advanced Solid Tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be pancreatic, lung (non-small cell), or colon cancer that has spread beyond the original site
- Your tumor must have a specific KRAS mutation (G12C, G12D, G12V, G12A, G12S, or G13D) confirmed by a biopsy or blood test
- You must have at least one measurable tumor visible on imaging scans
- You must be in good overall health—able to do light activities or be mostly confined to bed but not completely bedridden
- You must have received all standard cancer treatments available for your cancer type, unless your doctor explains why you cannot receive them
- You cannot have had any prior drugs that specifically target KRAS mutations
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This study tests a new drug called KQB368 for advanced solid cancers that have a specific genetic change (KRAS G12C or G12S mutation). The drug is designed to target this mutation and may help slow or shrink tumors in patients who don't have other curative treatment options.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.